Corcept Therapeutics (CORT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report). The ...

The best way to tell whether or not a piece of furniture on Amazon is good quality is by carefully considering the materials ...

Corcept Therapeutics (CORT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Investors might want to bet on Corcept Therapeutics (CORT), as earnings estimates for ... which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive ...

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has received an average recommendation of “Buy” from the five brokerages that are covering the company, MarketBeat reports.